Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;16(3):355-7.
doi: 10.5588/ijtld.11.0542.

Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs

E V Kurbatova  1 , J S Cavanaugh, N S Shah, A Wright, H Kim, B Metchock, A Van Deun, L Barrera, F Boulahbal, E Richter, N Martín-Casabona, F Arias, I Zemanova, F Drobniewski, A Santos Silva, C Coulter, R Lumb, J P Cegielski
Affiliations

Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs

E V Kurbatova et al. Int J Tuberc Lung Dis. 2012.

Abstract

Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6%). RMP-resistant isolates that were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not always a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications for use of molecular assays that identify only RMP resistance-associated DNA mutations.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest. All authors have denied any conflict of interest.

References

    1. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005–15. - PMC - PubMed
    1. World Health Organization. Anti-tuberculosis drug resistance in the world: fourth global report. Geneva, Switzerland: 2008.
    1. Bhanot N. Rapid molecular detection of tuberculosis. N Engl J Med. 2011;364(2):183. author reply 4–5. - PubMed
    1. WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world: third global report. Geneva. Geneva, Switzerland: 2004.
    1. WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997. Geneva, Switzerland: 1997. Anti-Tuberculosis Drug Resistance in the World.

MeSH terms

LinkOut - more resources